Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study

Please use this identifier to cite or link to this item: http://dspace.bits-pilani.ac.in:8080/jspui/xmlui/handle/123456789/2409

Full metadata record

DC Field	Value	Language
dc.contributor.author	Majumder, Syamantak	-
dc.date.accessioned	2021-10-02T17:47:01Z	-
dc.date.available	2021-10-02T17:47:01Z	-
dc.date.issued	2017-11-15	-
dc.identifier.uri	https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwjIwLySvKHzAhUFiOYKHaWqCb0QFnoECAIQAQ&url=https%3A%2F%2Fjournals.physiology.org%2Fdoi%2Fpdf%2F10.1152%2Fajprenal.00445.2017&usg=AOvVaw2kMwzJwNLNsB_p_BJcDksd	-
dc.identifier.uri	http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/2409	-
dc.description.abstract	Focal segmental glomerulosclerosis (FSGS) is characterized by proteinuria and renal function decline, leading to chronic kidney disease (CKD) and end-stage renal disease (ESRD; Ref. 15). Approximately 55% of patients with idiopathic FSGS with high-grade proteinuria will proceed to ESRD at 10 yr following diagnosis (40). The FSGS lesion can also develop as the end result of a spectrum of sources of glomerular injury, obesity, and reduced nephron mass. Despite current therapies including renin-angiotensin-aldosterone system (RAAS) inhibitors, antihypertensives, and immunosuppressants, clinical outcomes remain suboptimal.	en_US
dc.language.iso	en	en_US
dc.publisher	American Physiological Society	en_US
dc.subject	Biology	en_US
dc.subject	Dapagliflozin	en_US
dc.title	Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study	en_US
dc.type	Article	en_US
Appears in Collections:	Department of Biological Sciences

Files in This Item:

There are no files associated with this item.